PA8635101A1 - Nuevos derivados de aminopiridina y su uso como farmacos - Google Patents

Nuevos derivados de aminopiridina y su uso como farmacos

Info

Publication number: PA8635101A1
Authority: PA; Panama
Prior art keywords: sexual; disorder; disorders; compounds; dysfunction
Prior art date: 2004-05-27

Application number

PA20058635101A

Other languages

English (en)

Spanish (es)

Inventor

Allerton Charlotte Moira Norfor

Andrew Simon Cook

David Hepworth

Duncan Charles Miller

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-27

Filing date

2005-05-26

Publication date

2006-05-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8635101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-05-27 Priority claimed from GB0411891A external-priority patent/GB0411891D0/en

2004-06-03 Priority claimed from GB0412463A external-priority patent/GB0412463D0/en

2005-05-26 Application filed by Pfizer filed Critical Pfizer

2006-05-16 Publication of PA8635101A1 publication Critical patent/PA8635101A1/es

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
206010057671 Female sexual dysfunction Diseases 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
206010057672 Male sexual dysfunction Diseases 0.000 abstract 2
230000001568 sexual effect Effects 0.000 abstract 2
206010002652 Anorgasmia Diseases 0.000 abstract 1
208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
208000030047 Sexual desire disease Diseases 0.000 abstract 1
201000001880 Sexual dysfunction Diseases 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical class NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 1
229940052760 dopamine agonists Drugs 0.000 abstract 1
239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 1
230000005284 excitation Effects 0.000 abstract 1
208000014840 female orgasmic disease Diseases 0.000 abstract 1
201000001881 impotence Diseases 0.000 abstract 1
201000004197 inhibited female orgasm Diseases 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
231100000872 sexual dysfunction Toxicity 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Psychology (AREA)
Gynecology & Obstetrics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PA20058635101A 2004-05-27 2005-05-26 Nuevos derivados de aminopiridina y su uso como farmacos PA8635101A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0411891A GB0411891D0 (en)	2004-05-27	2004-05-27	New aminopyridine derivatives and their use as pharmaceuticals
GB0412463A GB0412463D0 (en)	2004-06-03	2004-06-03	New aminopyridine derivatives and their use as pharmaceuticals

Publications (1)

Publication Number	Publication Date
PA8635101A1 true PA8635101A1 (es)	2006-05-16

Family

ID=34970000

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PA20058635101A PA8635101A1 (es)	2004-05-27	2005-05-26	Nuevos derivados de aminopiridina y su uso como farmacos

Country Status (21)

Country	Link
EP (1)	EP1758862A1 (fr)
JP (1)	JP4198183B2 (fr)
AP (1)	AP2006003824A0 (fr)
AR (1)	AR049548A1 (fr)
AU (1)	AU2005247699A1 (fr)
BR (1)	BRPI0511571A (fr)
CA (1)	CA2567935C (fr)
EA (1)	EA200601982A1 (fr)
EC (1)	ECSP067029A (fr)
GT (1)	GT200500125A (fr)
IL (1)	IL179314A0 (fr)
MA (1)	MA28607B1 (fr)
MX (1)	MXPA06013786A (fr)
NL (1)	NL1029139C2 (fr)
NO (1)	NO20065326L (fr)
PA (1)	PA8635101A1 (fr)
PE (1)	PE20060366A1 (fr)
SV (1)	SV2005002129A (fr)
TW (1)	TW200609216A (fr)
UY (1)	UY28925A1 (fr)
WO (1)	WO2005115985A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0502509D0 (en) *	2005-02-07	2005-03-16	Pfizer Ltd	Novel salt form of a dopamine agonist
AU2010213192A1 (en) *	2009-02-13	2011-08-04	Bayer Intellectual Property Gmbh	Fused pyrimidines
MX347218B (es) *	2010-04-12	2017-04-20	Supernus Pharmaceuticals Inc	Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
US9504949B2 (en)	2011-06-30	2016-11-29	Donaldson Company, Inc.	Air/oil separator assemblies; components; and methods
GB2543296A (en)	2015-10-13	2017-04-19	Indivior Uk Ltd	Dopamine D3 receptor antagonists having a morpholine moiety
US10710980B2 (en)	2016-07-20	2020-07-14	Novartis Ag	Aminopyridine derivatives and their use as selective ALK-2 inhibitors
ES2897050T3 (es) *	2017-12-08	2022-02-28	Boehringer Ingelheim Int	Derivados de imidazopiridina y el uso de los mismos como medicamento
CA3136151A1 (fr) *	2019-04-12	2020-10-15	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Composes agonistes du recepteur d3; procedes de preparation; intermediaires de ceux-ci; et leurs procedes d'utilisation
CN115038443A (zh)	2019-11-22	2022-09-09	因西特公司	包含alk2抑制剂和jak2抑制剂的组合疗法
JP2023530316A (ja)	2020-06-16	2023-07-14	インサイト・コーポレイション	貧血の治療のためのａｌｋ２阻害剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5077290A (en) *	1990-10-11	1991-12-31	Merck & Co., Inc.	Morpholine derivatives compositions and use
GB0130219D0 (en) *	2001-12-18	2002-02-06	Pfizer Ltd	Compounds for the treatment of sexual dysfunction
NZ540505A (en) *	2002-12-10	2007-02-23	Pfizer	Morpholine derivatives for use as dopamine agonists in the treatment of I.A. sexual dysfunction

2005
- 2005-05-17 CA CA002567935A patent/CA2567935C/fr not_active Expired - Fee Related
- 2005-05-17 EA EA200601982A patent/EA200601982A1/ru unknown
- 2005-05-17 AU AU2005247699A patent/AU2005247699A1/en not_active Abandoned
- 2005-05-17 WO PCT/IB2005/001554 patent/WO2005115985A1/fr not_active Ceased
- 2005-05-17 BR BRPI0511571-0A patent/BRPI0511571A/pt not_active Application Discontinuation
- 2005-05-17 MX MXPA06013786A patent/MXPA06013786A/es not_active Application Discontinuation
- 2005-05-17 AP AP2006003824A patent/AP2006003824A0/xx unknown
- 2005-05-17 JP JP2007514200A patent/JP4198183B2/ja not_active Expired - Fee Related
- 2005-05-17 EP EP05747191A patent/EP1758862A1/fr not_active Withdrawn
- 2005-05-24 GT GT200500125A patent/GT200500125A/es unknown
- 2005-05-25 PE PE2005000583A patent/PE20060366A1/es not_active Application Discontinuation
- 2005-05-26 TW TW094117274A patent/TW200609216A/zh unknown
- 2005-05-26 UY UY28925A patent/UY28925A1/es not_active Application Discontinuation
- 2005-05-26 NL NL1029139A patent/NL1029139C2/nl not_active IP Right Cessation
- 2005-05-26 AR ARP050102169A patent/AR049548A1/es unknown
- 2005-05-26 PA PA20058635101A patent/PA8635101A1/es unknown
- 2005-05-27 SV SV2005002129A patent/SV2005002129A/es not_active Application Discontinuation
2006
- 2006-11-15 IL IL179314A patent/IL179314A0/en unknown
- 2006-11-20 NO NO20065326A patent/NO20065326L/no unknown
- 2006-11-27 EC EC2006007029A patent/ECSP067029A/es unknown
- 2006-11-27 MA MA29488A patent/MA28607B1/fr unknown

Also Published As

Publication number	Publication date
ECSP067029A (es)	2006-12-29
CA2567935C (fr)	2009-10-27
SV2005002129A (es)	2005-12-13
WO2005115985A1 (fr)	2005-12-08
GT200500125A (es)	2006-01-10
CA2567935A1 (fr)	2005-12-08
NL1029139C2 (nl)	2006-06-19
MA28607B1 (fr)	2007-05-02
PE20060366A1 (es)	2006-05-15
AR049548A1 (es)	2006-08-16
EA200601982A1 (ru)	2007-04-27
AU2005247699A1 (en)	2005-12-08
JP2008500331A (ja)	2008-01-10
MXPA06013786A (es)	2007-01-25
UY28925A1 (es)	2005-12-30
AP2006003824A0 (en)	2006-12-31
IL179314A0 (en)	2007-03-08
TW200609216A (en)	2006-03-16
EP1758862A1 (fr)	2007-03-07
NO20065326L (no)	2006-12-19
JP4198183B2 (ja)	2008-12-17
NL1029139A1 (nl)	2005-11-30
BRPI0511571A (pt)	2008-01-02

Publication	Publication Date	Title
CL2018000978A1 (es)	2018-08-24	Macrociclos peptídicos contra acinetobacter baumannii
CL2017001426A1 (es)	2018-02-16	Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2018000128A1 (es)	2018-06-15	Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
SV2016005257A (es)	2018-10-02	Benzimidazol-2-aminas como inhibidores de midh1
DOP2016000140A (es)	2016-06-30	Inhibidores de syk
DOP2011000260A (es)	2011-10-15	Pirimidinas fusionadas
GT201300055A (es)	2014-08-26	Formulacion de premezcla de dexmedetomidina
SV2011003809A (es)	2011-07-05	Derivados de heteroarilo como inhibidores de dgat1
MX381488B (es)	2025-03-12	Indoles para su uso en la infección por el virus de la gripe.
CL2012002905A1 (es)	2013-03-22	Compuestos derivados de heteroaril-ciclohexil-tetraazabenzo(e)azulenos sustituidos, moduladores del receptor de vasopresina v1a; procedimiento de preparacion; composición farmacéutica; y su uso para la prevención o el tratamiento de la dismenorrea, disfunción sexual masculina o femenina, ansiedad, entre otros.
DOP2010000079A (es)	2010-03-31	Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
ECSP10010032A (es)	2010-08-31	derivados de azaciclilisoquinolinona e -isoindolinona como antagonistas de la HISTAMINA-3
PA8635101A1 (es)	2006-05-16	Nuevos derivados de aminopiridina y su uso como farmacos
MX2018005589A (es)	2018-11-09	Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
CL2017003133A1 (es)	2018-04-13	Uso de derivados de bencimidazol para escape ácido nocturno
CL2017000827A1 (es)	2017-11-03	Inhibidores de aldosterona sintasa
SV2017005368A (es)	2017-05-12	[1,2,4] triazolo [4,3-b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
MX2022010939A (es)	2022-10-07	Novedosos derivados sustituidos como inhibidores de la d-aminoacido oxidasa (daao).
DOP2005000095A (es)	2005-06-14	Nuevos derivados de aminopiridina y su uso como farmacos
ECSP067024A (es)	2006-12-29	Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos
DOP2005000093A (es)	2005-11-30	Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos
SV2008002653A (es)	2008-04-11	Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
AR096322A1 (es)	2015-12-23	Derivados de pirimidin-4-il)oxi)-1h-indol-1-carboxamida y uso de los mismos
CU20100045A7 (es)	2011-09-21	Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
CR20140489A (es)	2014-12-24	Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t